NEW DELHI: Pharma major Lupin Ltd has received final approval from the USFDA to market sodium sulphate, potassium sulphate, magnesium sulphate oral solution used in the treatment of a form of cancer.
In a BSE filing, Lupin said: "it has received final approval for its sodium sulphate, potassium sulphate, magnesium sulphate oral solution, 17.5 g/3.13 g/ 1.6 g per ounces from the United States Food and Drug Administration (FDA) to market a generic version of Braintree Laboratories' Suprep Bowel Prep Kit."
Lupin said it will commence promoting the product shortly. The approved product is indicated for cleansing of the colon in the preparation for colonoscopy in adults. Suprep Bowel Prep Kit had US sales of USD 207.2 million. Shares of Lupin were trading 0.58 per cent higher at Rs 1,472.30 on the BSE.